Incyte
NEWS
As the third quarter of 2019 comes to an end, most biopharma companies are reporting their earnings as they head into the final lap for the year. Here’s a look at some of the bigger companies’ reports that came out this week.
Last week was busy for clinical trial news. Here’s a look.
The primary endpoint of the trial was improving overall response rate at Day 28 with Jakafi compared to the best available therapy.
There are high hopes for more M&A in the industry for the remainder of the year. Here’s a look at the 10 top takeover targets.
Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.
The investigational JAK inhibitor has hit the mark in three late-stage studies, with readouts from two more late-stage trials expected later this year.
With more than 16,000 attendees from 67 countries and hundreds, even thousands of presentations, it can be difficult to get a real grip on everything that went on at the 2019 BIO International Convention held in Philadelphia. Here’s a look at just a few of the highlights.
The approval of Jakafi marks the first approved treatment for this indication in the United States.
May has been a fairly slow month for approvals by the U.S. Food and Drug Administration (FDA). There are currently only two scheduled for the rest of the month, with a third that has been withdrawn. Let’s take a look.
JOBS
IN THE PRESS